https://scholars.lib.ntu.edu.tw/handle/123456789/528793
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liu J.-W. | en_US |
dc.contributor.author | Lee I.-K. | en_US |
dc.contributor.author | Tang H.-J. | en_US |
dc.contributor.author | Ko W.-C. | en_US |
dc.contributor.author | Lee H.-C. | en_US |
dc.contributor.author | Liu Y.-C. | en_US |
dc.contributor.author | PO-REN HSUEH | en_US |
dc.contributor.author | Chuang Y.-C. | en_US |
dc.creator | Liu J.-W.;Lee I.-K.;Tang H.-J.;Ko W.-C.;Lee H.-C.;Liu Y.-C.;Po-Ren Hsueh;Chuang Y.-C. | - |
dc.date.accessioned | 2020-12-18T08:39:23Z | - |
dc.date.available | 2020-12-18T08:39:23Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0003-9926 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/528793 | - |
dc.description.abstract | Background: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. Methods: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those with HBNCLs and those without HBNCLs. Patients were further divided into subgoups without fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). Results: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P=.006) and a higher proportion of shock at arrival at the medical center (P=.015) than the nonfatal subgroup. In group 2, the effect of a first- or secondgeneration cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P<.001); significant differences were found between the fatal and nonfatal subgroups in the APACHE II score (P<.001), number who were in shock at arrival at the medical center (P=.02), delayed surgical intervention (P=.03), and peripheral leukocytosis (P=.03). Shock at arrival at the medical center (odds ratio [OR], 19.25; 95% confidence interval [CI], 1.768-209.54; P=.02) was an independent risk factor for fatality in patients without HBNCLs. Use of a thirdgeneration cephalosporin and tetracycline or its analogue significantly reduced fatality rates in patients with HBNCLs (OR, 0.037; 95% CI, 0.007-0.192; P<.001). Conclusion: Septic shock is a determinant of fatality in patients with V vulnificus septicemia without HBNCLs; our data suggest that the combination of a third-generation cephalosporin and tetracycline or its analogue may be a better choice in antimicrobial treatment of V vulnificus septicemic patients with HBNCLs. ?2006 American Medical Association. All rights reserved. | - |
dc.relation.ispartof | Archives of Internal Medicine | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | amikacin; aminoglycoside; aminoglycoside derivative; antibiotic agent; cefotaxime; ceftazidime; ceftriaxone; cephalosporin; cephalosporin derivative; ciprofloxacin; clindamycin; doxycycline; gentamicin; latamoxef; minocycline; netilmicin; oxytetracycline; penicillin derivative; tetracycline; tetracycline derivative; tobramycin; adult; aged; APACHE; article; controlled study; demography; drug choice; drug effect; drug efficacy; fatality; female; human; leukocytosis; major clinical study; male; prescription; priority journal; prognosis; retrospective study; risk factor; septic shock; septicemia; skin necrosis; vesicular rash; Vibrio vulnificus; Aged; Anti-Bacterial Agents; APACHE; Bacteremia; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome; Vibrio Infections; Vibrio vulnificus | - |
dc.title | Prognostic factors and antibiotics in Vibrio vulnificus septicemia | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1001/archinte.166.19.2117 | - |
dc.identifier.pmid | 17060542 | - |
dc.identifier.scopus | 2-s2.0-33750355395 | - |
dc.relation.pages | 2117-2123 | - |
dc.relation.journalvolume | 166 | - |
dc.relation.journalissue | 19 | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-7502-9225 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。